Cargando…

Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study

In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colore...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudiman, Reno, Wijaya, Alma, Sribudiani, Yunia, Soedjana, Hardi Siswo, Wiraswati, Hesti Lina, Primastari, Etis, Nugraha, Prapanca, Lukman, Kiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205207/
https://www.ncbi.nlm.nih.gov/pubmed/37228916
http://dx.doi.org/10.1097/MS9.0000000000000694
_version_ 1785045986075213824
author Rudiman, Reno
Wijaya, Alma
Sribudiani, Yunia
Soedjana, Hardi Siswo
Wiraswati, Hesti Lina
Primastari, Etis
Nugraha, Prapanca
Lukman, Kiki
author_facet Rudiman, Reno
Wijaya, Alma
Sribudiani, Yunia
Soedjana, Hardi Siswo
Wiraswati, Hesti Lina
Primastari, Etis
Nugraha, Prapanca
Lukman, Kiki
author_sort Rudiman, Reno
collection PubMed
description In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and anti–human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. PATIENTS AND METHODS: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. RESULTS: Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). CONCLUSION: There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients.
format Online
Article
Text
id pubmed-10205207
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-102052072023-05-24 Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study Rudiman, Reno Wijaya, Alma Sribudiani, Yunia Soedjana, Hardi Siswo Wiraswati, Hesti Lina Primastari, Etis Nugraha, Prapanca Lukman, Kiki Ann Med Surg (Lond) Original Research In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and anti–human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. PATIENTS AND METHODS: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. RESULTS: Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). CONCLUSION: There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients. Lippincott Williams & Wilkins 2023-04-17 /pmc/articles/PMC10205207/ /pubmed/37228916 http://dx.doi.org/10.1097/MS9.0000000000000694 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Research
Rudiman, Reno
Wijaya, Alma
Sribudiani, Yunia
Soedjana, Hardi Siswo
Wiraswati, Hesti Lina
Primastari, Etis
Nugraha, Prapanca
Lukman, Kiki
Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title_full Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title_fullStr Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title_full_unstemmed Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title_short Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
title_sort identification of kras mutation and her2 expression in indonesian colorectal cancer population: a cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205207/
https://www.ncbi.nlm.nih.gov/pubmed/37228916
http://dx.doi.org/10.1097/MS9.0000000000000694
work_keys_str_mv AT rudimanreno identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT wijayaalma identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT sribudianiyunia identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT soedjanahardisiswo identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT wiraswatihestilina identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT primastarietis identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT nugrahaprapanca identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy
AT lukmankiki identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy